Ignite Creation Date:
2024-10-25 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533644
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castrate-Resistant Prostate Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
LEGION-100 A Phase 1b Open-Label Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed With Metastatic Castrate-Resistant Prostate Cancer mCRPC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the safety and tolerability of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose MTD andor selected dose for phase 2 study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None